HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs Retraction in /10.3892/ol.2024.14434

Xiong,Li; Zhen,Shuqing; Yu,Qionghua; Gong,Zuojiong

doi:10.3892/ol.2017.6433

HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs

Retraction in: /10.3892/ol.2024.14434

Authors:
- Li Xiong
- Shuqing Zhen
- Qionghua Yu
- Zuojiong Gong
View Affiliations

Affiliations: Department of Infectious Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Rheumatology, Hubei Xianning Ma Tang Rheumatism Hospital, Xianning, Hubei 437000, P.R. China, Department of Infectious Disease, Clinical Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China
Published online on: June 20, 2017 https://doi.org/10.3892/ol.2017.6433
Pages: 2141-2146
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Exosomal miRNAs are emerging as mediators of the interaction between mast cells (MCs) and tumor cells. The exosomal miRNAs can be internalized by liver cancer cells to inhibit cell metastasis. We explored the interaction between MCs and hepatocellular carcinoma (HCC) cells. We used hepatitis C virus E2 envelope glycoprotein (HCV‑E2) to stimulate MCs and harvest MCs‑derived exosomes to detect the miRNAs and changes of exosomal miRNAs before and after stimulation. Through miRNA microarray analysis, we identified 19 differentially expressed miRNAs in exosomes derived from MCs with or without HCV‑E2 treatment. HCV‑E2 not only increased the level of miRNA‑490 in MCs and their secreted exosomes but also increased the levels of miRNA‑490 in recipient HepG2 cells, which ultimately inhibited the ERK1/2 pathway. The transfection of antagomiR‑490 significantly decreased the levels of miR‑490 in MCs, MCs‑derived exosomes, and recipient HepG2 cells and increased migration of HepG2, indicating that miR‑490 is involved in the regulation of HepG2 cell migration. The present study suggests that MCs can inhibit HCC cell metastasis by inhibiting the ERK1/2 pathway by transferring the exosomal shuttle microRNAs into HCC cells, which provides new insights for the biological therapy of HCC induced by hepatitis C.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Liu Y, Zhang JB, Qin Y, Wang W, Wei L, Teng Y, Guo L, Zhang B, Lin Z, Liu J, et al: PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology. 58:692–705. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yamashita A, Saito T, Akaike K, Arakawa A, Yoshida A, Kikuchi K, Sugitani M and Yao T: Mast cell sarcoma of the sternum, clonally related to an antecedent germ cell tumor with a novel D579del KIT mutation. Virchows Arch. 470:583–588. 2017. View Article : Google Scholar : PubMed/NCBI
4	Miłek K, Kaczmarczyk-Sekuła K, Strzępek A, Dyduch G, Białas M, Szpor J, Gołąbek T, Szopiński T, Chłosta P and Okoń K: Mast cells influence neoangiogenesis in prostatic cancer independently of ERG status. Pol J Pathol. 67:244–249. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lampiasi N, Azzolina A, Montalto G and Cervello M: Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med. 39:284–294. 2007. View Article : Google Scholar : PubMed/NCBI
6	Tu JF, Pan HY, Ying XH, Lou J, Ji JS and Zou H: Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma. Medicine (Baltimore). 95:e32202016. View Article : Google Scholar : PubMed/NCBI
7	Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A and Rodríguez-Dorantes M: MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther. 7:1327–1338. 2014.PubMed/NCBI
8	Wang J, Yao Y, Wu J and Li G: Identification and analysis of exosomes secreted from macrophages extracted by different methods. Int J Clin Exp Pathol. 8:6135–6142. 2015.PubMed/NCBI
9	Cocucci E, Racchetti G and Meldolesi J: Shedding microvesicles: Artefacts no more. Trends Cell Biol. 19:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dreyer F and Baur A: Biogenesis and functions of exosomes and extracellular vesicles. Methods Mol Biol. 1448:201–216. 2016. View Article : Google Scholar : PubMed/NCBI
11	Sabahi A, Uprichard SL, Wimley WC, Dash S and Garry RF: Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol. 88:10280–10288. 2014. View Article : Google Scholar : PubMed/NCBI
12	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25:501–515. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Yi J, Chen X, Zhang Y, Xu M and Yang Z: The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10. Oncol Lett. 11:1527–1530. 2016.PubMed/NCBI
15	Ko SF, Yip HK, Zhen YY, Lee CC, Lee CC, Huang CC, Ng SH and Lin JW: Adipose-derived mesenchymal stem cell exosomes suppress hepatocellular carcinoma growth in a rat model: Apparent diffusion coefficient, natural killer T-cell responses, and histopathological features. Stem Cells Int. 2015:8535062015. View Article : Google Scholar : PubMed/NCBI
16	Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL, Hardman C, Xue L, Cerundolo V and Ogg G: Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 213:2399–2412. 2016. View Article : Google Scholar : PubMed/NCBI
17	Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, Cheng K and Zou W: miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2. Gene. 593:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
18	Xu X, Chen R, Li Z, Huang N, Wu X, Li S, Li Y and Wu S: MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFβR1. BMC Cancer. 15:10232015. View Article : Google Scholar : PubMed/NCBI
19	Chen S, Chen X, Xiu YL, Sun KX and Zhao Y: MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. Cancer Lett. 362:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang LY, Liu M, Li X and Tang H: miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 288:4035–4047. 2013. View Article : Google Scholar : PubMed/NCBI
21	Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y and Zhang Z: HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother. 88:421–429. 2017. View Article : Google Scholar : PubMed/NCBI
22	Guo T, Zhao L, Zhang Y, Liu G, Yao Y and Li H: A monoclonal antibody targeting the dimer interface of epidermal growth factor receptor (EGFR). Immunol Lett. 180:39–45. 2016. View Article : Google Scholar : PubMed/NCBI
23	Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W and Wan Y: Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 266:249–262. 2008. View Article : Google Scholar : PubMed/NCBI
24	Higuchi T, Todaka H, Sugiyama Y, Ono M, Tamaki N, Hatano E, Takezaki Y, Hanazaki K, Miwa T, Lai S, et al: Suppression of microRNA-7 (miR-7) biogenesis by nuclear factor 90-nuclear factor 45 complex (NF90-NF45) controls cell proliferation in hepatocellular carcinoma. J Biol Chem. 291:21074–21084. 2016. View Article : Google Scholar : PubMed/NCBI